Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET
Original post:
Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021
AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Citi’s 2021 Virtual Immuno-Oncology Day Conference being held virtually February 17-18, 2021.
View post:
Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day
TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has closed its previously announced bought deal prospectus offering of 46,000,000 units (“Units”) at a price of $0.50 per Unit for aggregate gross proceeds of $23,000,000 (the “Offering”), which includes the exercise in full of the 15% over-allotment option. The syndicate of underwriters was led by Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (together, the "Underwriters"). The Units were offered and sold by way of a short form prospectus filed with the securities commissions in each of the provinces of Canada, other than Québec.
See the original post here:
Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering
Delisting of AS „Grindeks” shares from the Baltic Main list
Go here to see the original:
Delisting of AS „Grindeks” shares from the Baltic Main list
Bagsværd, Denmark, 12 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Continued here:
Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021
NEW YORK, NY , Feb. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as an ongoing Pharmaceutical Development initiative, today announced that it has commenced development of its 1st full spectrum Cannabidiol (“CBD”) infused edibles product line. The Company plans to develop this above referenced product line, with the following attributes: Kosher Certified, Halal Certified, Vegan Formulation, Dairy-Free, Infused with Full Spectrum Hemp Extract (“Full Spectrum”), All-Natural Flavors, Sugar Free/Diabetic Friendly Version(s), and Full Adherence to U.S. Federal Laws & Regulations. The Company expects to provide concrete details about this proposed full spectrum product line within the near term.
See the original post here:
Tauriga Sciences Inc. to Commence Development of its 1st Full Spectrum CBD Infused Edibles Product Line
In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained reductions in disease-specific biomarkers, denoting clear biologic effects
BOSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a business update on the abaloparatide global business. Progress was made, and continues to be made, across the following areas.
More here:
Radius Health, Inc. Provides Abaloparatide Business Update
Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use
Here is the original post:
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the...
Continue reading here:
Tauriga Sciences, Inc. Now Configured to Accept the Following Cryptocurrencies as Payment Options on Its E-Commerce Platform: Bitcoin (BTC), Etherium...
Nes Ziona, Israel, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced the closing of its previously announced offering of 2,296,107 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of $20.00 per ordinary share, less underwriting discounts and commissions.
Here is the original post:
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
See the original post:
Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock
Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx
See the rest here:
Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx
Here is the original post:
Neck Hammock Reviews – Does this gadget really help? – Product Review by Mike Vaughn
Nanotechnology in Medical Applications: The Global Market
This report discusses the implications of technology and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting nanomedicine are reviewed, and the nature and structure of the nanomedicine industry are discussed with profiles of the leading 60+ companies, including recent merger and acquisition (M&A) activity. Five-year sales forecasts are provided for the national markets including the major therapeutic categories of products involved. Specific product categories quantified include diagnostics, cancer, CNS, anti-infective agents, cardiovasculars and anti-inflammatories.
Also Read:https://telegra.ph/Global-Dancewear-Market-Statistics-Development-and-Growth-2025-02-02
Report Includes:
An overview of the global markets for nanotechnology used in medical applications
Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
A review of technologies involved, in-depth analysis of applications in practice, and evaluation of future or potential applications
Also Read: https://techsite.io/p/1944999
Information on many significant products in which the nano dimension has made a significant contribution to product effectiveness
A look at the regulatory environment, healthcare policies, demographics, and other factors that directly affect nanotechnology used in medicine
Analysis of the markets dynamics, specifically growth drivers, inhibitors, and opportunities
Coverage of strategies employed by companies specializing in nanomedicine to meet the challenges of this highly competitive marketSummary
Also Read:https://wiseguyreports12.blogspot.com/2021/02/global-china-digital-audio-broadcasting.html
Nano-enabled medical products began appearing on the market over a decade ago, and some have become best-sellers in their therapeutic categories. The principal areas in which nanomedical products have made an impact are cancer, CNS diseases, cardiovascular disease and infection control. The Summary Table gives estimates of the historical and current markets for these nanomedicine areas with a forecast through 2022.
The U.S. market is by far the largest in the global nanomedicine market and is set to continue to dominate the world marketplace; however, other national markets are expected to increase their shares over the next five years.
Reasons for Doing the Study
Also Read:https://penzu.com/p/240d32a5
Nanomedicine is already an established market. Unlike some other potential applications of nanotechnology, which are still largely experimental, nanomedicine has already produced some significant products in which the nano dimension has made a significant contribution to product effectiveness. Now that aspects of the nanomedicine market are established, it is appropriate to review the technology, see its practical applications so far, evaluate the participating companies and look to its future.ABLYNX NV
ABRAXIS BIOSCIENCE (CELGENE)
APHIOS CORP.
BIOFORCE NANOSCIENCES HOLDINGS INC.
BIO-GATEAG
CALANDO PHARMACEUTICALS INC.
C SIXTY INC. (ARROWHEAD PHARMACEUTICALS)
ELAN (ALKERMES CORP.)
FARFIELD SCIENTIFIC (BIOLIN SCIENTIFIC AB)
IGI LABORATORIES (TELIGENT INC.)
KEREOS INC.
KEYSTONE NANO INC.
KLEINDIEK NANOTECHNIKGMBH
LABOPHARM (PALADIN LABS)
LIPLASOME PHARMA APS
MAGFORCE NANOTECHNOLOGIES
MAGNAMEDICS GMBH
MICROFLUIDICS CORP.
MOLECULAR PROFILES (JUNIPER PHARMA SERVICES)
NANOBIO CORP.
NANOBIOTIX
NANOCARRIER CO. LTD
NANOCOPOEIA, INC.
NANOCYTE INC.
NANOLOGIX INC.
NANOMED PHARMACEUTICALSINC.
NANOMIX INC.
NANOPHARM AG
NANOSPECTRA BIOSCIENCESINC.
NANOSPHERE INC. (LUMINEX CORP.)
NANOSTRUCTURES INC.
NANOSYN INC.
NANOTHERAPEUTICS INC.
NANOTROPE INC.
NANOVIRICIDES INC
NUCRYST PHARMACEUTICALS
NUTRALEASE
ORTHOVITA INC. (STRYKER CORP.)
PIONEER SURGICAL TECHNOLOGY (RTI SURGICAL)
PSIVIDA LTD.
SOLUBEST LTD
STARPHARMA
TECANGROUP LTD.
TRANSGENEX NANOBIOTECH INC.
FOR MORE DETAILS :https://www.wiseguyreports.com/reports/5545026-global-plastic-and-competitive-pipe-market-insights-and-forecast-to-2016
About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Contact Us:
NORAH TRENT
[emailprotected]
Ph: +162-825-80070 (US)
Ph: +44 2035002763 (UK)
Here is the original post:
Global NANOTECHNOLOGY IN MEDICAL APPLICATIONS Statistics, CAGR, Outlook, and Covid-19 Impact 2016 The Bisouv Network - The Bisouv Network
TheNanotechnology in Medical market outlooklooks extremely promising is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehensive data that enhances the understanding, scope and application of this report.
The report presents the market competitive landscape and a corresponding detailed analysis of the majorvendor/key playersin the market.Top Companiesin the Global Nanotechnology in Medical Market:Smith and Nephew, Novartis, Merck, Mitsui Chemicals, Amgen, Cytimmune, Access, Camurus, Roche, Dentsply International, 3M, Celgene, Pfizer.
SPECIAL OFFER (Avail an Up-to 25% discount on this report, please fill the form and mention the code: MIR25 in the comments section)
Click the link to get a free Sample Copy of the Report@:
This report segments the global Nanotechnology in Medical market on the basis ofTypesare:
Nano Medicine
Nano Diagnosis
Other
On the basis ofApplication, the Global Nanotechnology in Medical market is segmented into:
Hospitals
Clinics
Others
Investigator Observers Strong Growth in Specific Regions:
EuropeMarket (Germany, UK, France, Russia, Italy)
Center East and AfricaMarket (Saudi Arabia, UAE, Egypt, Nigeria, South Africa)
South AmericaMarket (Brazil, Argentina, Colombia)
North AmericaMarket (United States, Canada, Mexico)
Asia PacificMarket (China, Japan, Korea, India, Southeast Asia).
Inquire For Discount at:
Influence of the Nanotechnology in Medical market report:
-Comprehensive assessment of all opportunities and risk in the Nanotechnology in Medical market.
-Nanotechnology in Medical market recent innovations and major events
-Detailed study of business strategies for growth of the Nanotechnology in Medical market-leading players.
-Conclusive study about the growth plot of Nanotechnology in Medical market for forthcoming years.
-In-depth understanding of Nanotechnology in Medical market-particular drivers, constraints and major micro markets.
-Favorable impression inside vital technological and market latest trends striking the Nanotechnology in Medical market.
Important Features that are under Offering and Key Highlights of the Reports:
Detailed overview of Market
Changing market dynamics of the industry
In-depth market segmentation by Type, Application etc.
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape of Market
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth.
Finally, the Nanotechnology in Medical Market report is the believable source for gaining the market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request, and market development rate and figure, and so on. Nanotechnology in Medical Industry report additionally Presents a new task SWOT examination, speculation attainability investigation, and venture return investigation.
We also offer customization on reports based on specific client requirement:
1-Freecountry level analysis forany 5 countriesof your choice
2-FreeCompetitive analysis ofany 5 key market players.
3-Free40 analyst hoursto cover any other data points.
About Us:
MarketInsightsReportsprovides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.MarketInsightsReportsprovides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
MediaContact Us:
Irfan Tamboli (Head of Sales) Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com
See the article here:
Nanotechnology in Medical Market Demand Analysis To 2026 Lead By-Smith and Nephew, Novartis, Merck, Mitsui Chemicals, Amgen, Cytimmune KSU | The...
AZoM speaks withDr. Iman Roohani from UNSW.Dr.Roohani is part of a team of researchersthat developed a technique referred to as Ceramic Omnidirectional Bioprinting in Cell-Suspensions (COBICS). This techniquecould allow surgeons to print structures that can be submerged in water and hardened within just minutes, resembling natural bone.Even more revolutionary, the structures contain living cells that continue to grow after they are implanted.
We have developed a technique (COBICS) that enables printing constructs with the same chemistry to native bone mineral at room temperature with living cells. These structures are the most accurate mimics of the bone tissue. COBICS can print complex and biologically relevant architecture constructs without the need for sacricial support materials, on-spot and laborious post-processing steps.
COBICS has two main components. A chemically cross-linked microhydrogel bath with optimized yield-stress properties that support the printing of the ceramic ink, the second component, in the presence of live cells. The ink is a calcium phosphate paste with a specific formulation that allows the material to be used directly in the aqueous environment, without the need for any post-processing steps, such as high-temperature treatments, that are required for other types of existing ceramic materials.
Once ink comes in contact with the microgel, nanocrystalization kicks off at the interface between ink and hydrogel, which further locks the filament in place. Since this ink can harden quickly without imposing adverse effects on living cells, COBICS enables printing within a suspension of living cells to achieve complex bone shapes, where the cells integrate to form natural bone tissue.
Traditional bone grafts, particularly synthetic ones, are mostly fabricated from ceramic materials at high temperatures, which disallows integration with cells and growth factors. Moreover, due to high temperature processing, the microstructure of such grafts does not resemble the native bone.
COBICS paves the way to fabricate autologous graft like structures in the laboratory, which significantly reduces the risks and drawbacks involved in harvesting these grafts from the patient in the clinical setting by using only cells from the patient or other sources of regenerative cells. This also could enable patient-specific real-time bone reconstruction where the bioprinter could directly print new bone into the resected space.
You could even isolate the patient's stem cells before surgery for inclusion with the ink to improve the integration of the new bone into the surgery site or in dental reconstruction. In another example, drugs could be integrated with the ink for sustained release over time to increase natural bone formation, combat bacteria, or influence the immune system (e.g., enhance wound healing).
The ink has an essential role in printing the constructs by the COBICS technique. The optimization process of formulating the ink took around 2 years since we had to ensure that ink has several properties that were mutually exclusive. Those properties included biocompatibility, being printable, proper setting time, adequate strength and firmness after printing, and printing in contact with the microgel bath.
We have an ongoing animal study at the moment, that will hopefully confirm our hypothesis that there should be no harmful components in our material.Thus far, all of our tests with human cells in the laboratory have confirmed high biocompatibility. We plan to scale up our production of bone-like grafts and test the regenerative properties of the printed grafts in large animal models before proceeding with humantrials and regulatory approval.If everything goes well and we findexternal funding support,we are optimistic the technique may be ready for the clinic within 5 years.
Readers can check out the full article at https://doi.org/10.1002/adfm.202008216.
From 2010 to 2014, Dr. Roohani studied and received his Ph.D. degree at the School of Aerospace, Mechanical and Mechatronic Engineering at the University of Sydney (USYD) in Sydney, Australia. From 2016 to 2020, he worked in the field of biomaterials and tissue engineering as the National Health and Medical Research Council (NHMRC) early career fellow, first in the biomedical engineering department at the University of Sydney, and then at the School of Chemistry in the University of New South Wales (UNSW).
Dr. Roohani is interested in the use of biomaterials as the bone substitute, drug delivery and instructive source for cells. More specifically, his interests comprise synthesis and development of a range of bioceramics, including calcium phosphates, understanding of the interaction between living cells and synthetic substrates, and translation of the application of these materials and concepts to clinical applications.
Dr. Roohani is the inventor of several patented products, including the COBICs techniques. He is the author of more than 60 peer-reviewed publications (h index of 23), book chapters, and 3 patent applications.
ResearchGate: https://www.researchgate.net/profile/Iman_Roohani
Twitter: @ImanRoohani
Email:[emailprotected]
Google Scholar:https://scholar.google.com.au/citations?user=NyzEeygAAAAJ&hl=en
Disclaimer: The views expressed here are those of the interviewee and do not necessarily represent the views of AZoM.com Limited (T/A) AZoNetwork, the owner and operator of this website. This disclaimer forms part of the Terms and Conditions of use of this website.
See the original post:
Using 3D Printing to Develop Bone-Like Structures that Contain Living Cells - AZoM
The report provides study at global and regional level to provide comprehensive value market analysis for the years (2017 & 2018 Historic Years, 2019 Base Year and 2020-2027 Forecast Period). The Tooth Regeneration Market research report is a wide-ranging study of current trends, market growth drivers, and restraints. Each market segment is broadly analyzed at a powdered level by region (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America) to provide thorough information on the global and regional level.
Tooth regeneration is a regenerative surgical technique based on stem cells that is used in the fields of tissue engineering and stem cell biology. By developing it from autologous stem cells, the tooth regeneration procedure restores the weakened or missing tooth. With the aid of reabsorbable biopolymer, somatic cells are harvested and reprogrammed to stimulate pluripotent stem cells and dental lamina.
Some of the key players in this market include
Download Sample PDF Brochure of this research study at https://www.theinsightpartners.com/sample/TIPRE00018967/
The Tooth Regeneration Market is segmented on the basis of services and application. Based on services , the market is segmented as Medical Writing and Publishing, Medical Monitoring, Medical Science Liaisons (MSLs), Medical Information, Others. Based on application, the market is segmented as pharmaceutical, biopharmaceutical, medical devices.
The segmentation in this research study has been finalized post in-depth secondary research and extensive primary research. In addition, the market is also segmented on the basis of technology offered by the leading participants in the industry in order to understand widely used market specific terminologies. Thus, we have incorporated the segments of the research and have finalized the market segmentation.
The Insight Partners Tooth Regeneration Market Research Report Scenario includes:
Order a copy of this research study at https://www.theinsightpartners.com/buy/TIPRE00018967/
The report also covers a detailed chapter of the analysis on COVID-19 impact on this market at global and regional level in our final reports.
This research provides detailed information regarding the major factors influencing the growth of the Tooth Regeneration Market in Global and Regional Level (drivers, restraints, opportunities, and challenges), forecast of the market size, in terms of value, market share by region and segment; regional market positions; segment and country opportunities for growth; New product developments, strengths and weaknesses, brand portfolio; Marketing and distribution strategies; challenges and threats from current competition and prospects; Key company profiles, SWOT, product portfolio and growth strategies.
ABOUT US:
The Insight Partners is a one stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Our research model is very simple. We believe in client servicing and delivering best quality to our customers. Through our research content, we are making sure that our customers get value of their money along with better quality data and analysis.
Our research content is majorly focused towards market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis etc. We provide detailed break-up of segmentation in terms of geography, technology, product and services etc.; which helps our clients to get a deeper analysis on various research topics.
Contact US:
If you have any queries about this report or would like further information, please contact us:
North America: +1 646 491 9876
Asia-Pacific: +91 20 6727 8686
Email: [emailprotected]
Go here to see the original:
Tooth Regeneration Market to Exhibit Steadfast Expansion by 2027 | Unilever, Ocata Therapeutics, Integra LifeSciences, CryoLife, BioMimetic...
Generations of students have learned that the central nervous system has immune privilege. This means that to an extent the immune system tolerates the presence of foreign proteins, or antigens, and tissue in the brain and spinal cord.
The immune system cannot respond in the usual way to infections, injuries, or tumors in the brain and spinal cord, because the blood-brain barrier prevents immune cells from entering or leaving.
Despite this, scientists know that inflammation plays a pivotal role in many neurological and psychiatric conditions, including Alzheimers disease, MS, autism, and schizophrenia.
So the question remains, if there is no exchange of information, how does the immune system respond to and influence the brain in such a broad range of conditions?
A team of scientists led by Washington University School of Medicine in St. Louis, MO, have discovered that immune cells are stationed in the dura mater, which is the tough outer membrane of the brain.
From this vantage point, they monitor the cerebrospinal fluid draining from the brain. If they detect the molecular calling cards of infection, cancer, or injury, they can mount an immune response.
The research appears in the journal Cell.
Every organ in the body is being surveilled by the immune system, says senior author Dr. Jonathan Kipnis, Alan A. and Edith L. Wolff Distinguished Professor of Pathology and Immunology.
He explains:
If there is a tumor, an injury, an infection anywhere in the body, the immune system has to know about it. But people say the exception is the brain; if you have a problem in the brain, the immune system just lets it happen. That never made sense to me. What we have found is that there is indeed immune surveillance of the brain it is just happening outside the brain.
In 2015, a study in mice revealed a network of vessels in the dura mater that drains cerebrospinal fluid from the brain into lymph nodes in the neck. Also in 2015, a study led by Dr. Kipnis recorded similar findings in both mice and humans.
Lymph nodes are part of an extensive network of fluid-filled vessels known as the lymphatic system. An accumulation of pathogens in lymph nodes can lead to the initiation of an immune response.
This suggested a more intimate connection between the brain and immune system than previously suspected. However, it remained unclear exactly where and how immune cells surveil the contents of the cerebrospinal fluid as it drains from the brain.
Dr. Kipnis and his colleagues knew that the lymph vessels that carry fluid from the brain run alongside blood-filled cavities, or sinuses, in the dura mater.
Crucially, the walls of these sinuses are more permeable than the blood vessels of the blood-brain barrier.
Following up this clue, the scientists showed in their experiments that small molecules from the brain and immune cells accumulate in the sinuses.
Some of the cells, known as antigen presenting cells, which include dendritic cells, pick up suspicious molecules and present them to other immune cells, called T cells, which patrol the body in the bloodstream.
When they bind to these suspect molecules, the T cells can initiate an immune response.
Dr. Justin Rustenhoven, a postdoctoral researcher and the first author of the new paper, says the brain must be shielded from the full force of the immune system.
Immune activity in the brain can be highly detrimental, he says. It can kill neurons and cause swelling. The brain cannot tolerate much swelling, because the cranium is a fixed volume. So immune surveillance is pushed to the borders, where the cells can still monitor the brain but do not risk damaging it.
Dr. Kipnis uses a metaphor to explain how immune cells in the dural sinuses monitor the contents of cerebrospinal fluid for unfamiliar proteins or antigens:
Imagine if your neighbors went through your trash every day. If they start finding blood-stained towels in your trash, they know something is wrong. It is the same thing with the immune system. If patrolling immune cells see tumor antigens or signs of infection from the brain, the cells know there is a problem. They will take that evidence to immune headquarters, which is the lymph nodes, and initiate an immune response.
The findings offer promising opportunities for treating brain disorders that involve autoimmune attacks on tissue.
In MS, for example, the immune system degrades the myelin sheath, which is the fatty insulating material that protects nerve cells.
Future treatments could target immune cells in the sinuses of the dura mater to prevent them from initiating certain immune responses in the brain.
Now that we know where it is happening, that opens up lots of new possibilities for modulating the immune system, says Dr. Kipnis.
Excerpt from:
How the immune system watches over the brain - Medical News Today
Immunai, a startup developing an AI platform to analyze the human immune system, today announced that it raised $60 million. The company says it will use the funds to broaden its functional genomics capabilities and help its partners prioritize, discover, and develop new therapies and drug combinations.
Emerging treatments like gene cell therapies and cancer immunotherapies promise to revolutionize the field of medicine. But the immune systems complexity trillions of cells partitioned into hundreds of types and states that interplay with various systems and proteins threatens to stymie research. In 1999, a patient in a trial died after an immune system attack likely resulting from preexisting antibodies against a virus used as part of gene therapy a death that experts believe led to years lost in gene therapy development. Immunai aims to prevent such mistakes with immune profile-generatingAI.
Immunai was founded in 2018 by Noam Solomon, an ex-Harvard and -MIT postdoctoral researcher, and Luis Voloch, an MIT graduate and former machine learning engineer at Palantir. The two teamed up with members of the Parker Institute, which works with researchers to accelerate the development of immune therapies, to pursue a platform that sheds light on cell populations post- and pre-treatments.
When I met my cofounder Luis, I was a math postdoc at MIT and Luis was working to apply machine learning to biology. Together, we wanted to bring transfer learning AI methods to what we believe would solve the biggest problem in society today disease, Solomon told VentureBeat via email. All disease can be traced back to the immune system. But what Luis and I realized is that pharmaceutical companies dont have access to any comprehensive, granular insight into how the immune system works, how it responds to the drugs or therapies theyre developing, and what patients are most likely to benefit.
Immunais tech records over a terabyte of data from a blood sample, profiling cells at what the company characterizes as unprecedented depth. Samples are compared with a database using AI that maps data to hundreds of cell types and states, creating immune profiles.
Its an approach similar to that of scientists affiliated with the Human Vaccines Project, who are working to identify biomarkers i.e., indicators of particular disease states that predict immune responses to vaccines and cell therapies. Microsoft and startup Adaptive Biotechnologies are also collaborating to develop algorithms that create a translation map for cell receptors to antigens, or pathogen molecules that trigger an immune response, and map those antigens back to diseases.
Clinical studies have traditionally focused on testing thousands or even tens of thousands of subjects and collecting a limited amount of data on each. But massive corpora and AI enable millions of data points to be collected about a single individual.
The immune system is implicated in nearly every illness, making our technology critical for identifying, diagnosing, and treating disease, from cancer to autoimmune disorders, Solomon said in a statement. Our expansion into functional genomics will help our partners tackle their most pressing questions in therapy development, and will ultimately improve the lives of many patients.
Immunais immune profiles could support the discovery of biomarkers by spotting changes in cell type and expression. For example, the Immunai team characterized a CAR-Natural Killer T (NKT) infusion cell therapy product developed at the Baylor College of Medicine for use in neuroblastoma patients. Baylor researchers and Immunai identified a gene potentially involved in CAR-NKT-mediated killing of tumor cells and are working to validate it. Elsewhere, Immunai says its engaging with commercial partners to develop cell therapy candidates in solid tumors.
Voloch says that Immunai is working with 5 of the worlds largest pharma companies in addition to institutions including Stanford, Harvard, Memorial Sloan Kettering, and the University of Pennsylvania. Weve developed a novel platform to reprogram immunity by mining AMICA, our proprietary harmonized single-cell immunology database, with cutting-edge transfer and multi-task learning algorithms, he added. Our vertically integrated functional genomics and AI capabilities allow us to prioritize and validate targets more accurately.
Seventy-employee Immunai is headquartered in New York City, with offices in San Francisco and Tel Aviv. The series A round announced today was led by the Schusterman Foundation, the Duquesne Family, Catalio Capital Management, and Dexcel Pharma. Existing investors Viola Ventures and TLV Partners also participated, bringing Immunais total raised to date to $80 million.
See the original post:
Immunai raises $60 million to analyze the immune system with AI - VentureBeat